21 March 2022

Sports Medicine technology for joint repair and connected arthroscopic tower during AAOS 2022 Annual Meeting

Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology business, today announces it will showcase its latest Sports Medicine innovations for joint repair and arthroscopic enabling technologies during the American Academy of Orthopaedic Surgeons 2022 Annual Meeting being held in Chicago, IL. The latest technologies include:

FAST-FIX◊ FLEX Meniscal Repair System: A surgeon-guided, bendable needle and shaft providing access to all zones of the meniscus.1-3 Improving access leads to a greater opportunity to repair the meniscus rather than remove it, which can result in long-term benefits to the patient.4-6

FAST-FIX FLEX Meniscal Repair System

INTELLIO◊ Connected Tower: Brings together Smith+Nephew’s leading capital technologies across its INTELLIO IMAGING, INTELLIO RESECTION and INTELLIO FLUID & ACCESS portfolios to deliver the “Power of Unity” to customers. Using a centralized app to wirelessly connect and control the major components of an arthroscopy surgical tower from outside the sterile field, the INTELLIO Connected Tower and its portfolios help to streamline procedure support. Recent advancements to the connected tower include a new DOUBLEFLO◊ Pump and 4KO◊ Scopes optimized for 4K resolution imaging.  

WEREWOLF◊ FASTSEAL 6.0 Hemostasis Wand: Using low temperature thermal energy7, the WEREWOLF FASTSEAL 6.0 Hemostasis Wand delivers hemostatic sealing (via coagulation) during open orthopaedic procedures such as total joint arthroplasty (TJA). This technology has been shown to significantly reduce total blood loss*8 as well as significantly shortening procedure time.**9 The WEREWOLF FASTSEAL 6.0 Hemostasis Wand can be utilized alongside Smith+Nephew’s novel ABLE◊ Advanced Anterior Approach for total hip arthroplasty (THA). ABLE is a minimally invasive, muscle-sparing approach with no barriers to adoption, complementing a value-based system of limiting healthcare dollar spend while maintaining or improving patient outcomes when compared with the direct anterior approach.10

REGENETEN◊ Bioinductive Implant: Supports the body’s natural healing response by inducing the growth of new tendon-like tissue11-14 to biologically augment the existing tendon and disrupt disease progression.11-16 The implant is about the size of a postage stamp and has been shown to be completely resorbed within six months.***13,17 In addition to rotator cuff repair, the REGENETEN Bioinductive Implant is marketed in the United States for Gluteus Medius hip repair as well as Achilles repair.

CAP-FIX◊ Suture Passer: A direct style passer designed specifically for the passage and retrieval of suture through the hip capsule to facilitate capsular closure. Optimized for sharpness, strength, trajectory and suture throw, the device is available in 45 and 70 degree angles.18-19 It is compatible with Vicryl™ Size #2 (a specific absorbable suture) as well as other Smith+Nephew standard suture offerings.18 The Suture Passer is the latest offering from Smith+Nephew’s CAP-FIX Capsular Management Family and joins an innovative suite of flagship hip preservation products that encourages surgeons to “Go Beyond the Repair” for hip repair solutions. 

To learn more about these ground-breaking Sports Medicine innovations, please stop by the Smith+Nephew booth (#831) during AAOS 2022.

Enquiries

Media

 

David Snyder

+1 978-749-1440

Smith+Nephew

 

*Bipolar radiofrequency hemostasis device compared to monopolar electrocautery for THA using an anterolateral approach (p=0.0001, n=50)

**Bipolar radiofrequency hemostasis device compared to monopolar electrocautery for infected revision total knee arthroplasty (TKA)(p=0.044, n=80)

***On human biopsy (n=1) and in-vivo sampling

^For an adjustable fixation device; as demonstrated in bench top testing

 

About Smith+Nephew

Smith+Nephew is a portfolio medical technology business focused on the repair, regeneration and replacement of soft and hard tissue. We exist to restore people’s bodies and their self-belief by using technology to take the limits off living. We call this purpose ‘Life Unlimited’. Our 18,000 employees deliver this mission every day, making a difference to patients’ lives through the excellence of our product portfolio, and the invention and application of new technologies across our three global franchises of Orthopaedics, Sports Medicine & ENT and Advanced Wound Management.

Founded in Hull, UK, in 1856, we now operate in more than 100 countries, and generated annual sales of $5.2 billion in 2021. Smith+Nephew is a constituent of the FTSE100 (LSE:SN, NYSE:SNN). The terms ‘Group’ and ‘Smith+Nephew’ are used to refer to Smith & Nephew plc and its consolidated subsidiaries, unless the context requires otherwise.

For more information about Smith+Nephew, please visit www.smith-nephew.com and follow us on Twitter, LinkedIn, Instagram or Facebook.

Forward-looking Statements

This document may contain forward-looking statements that may or may not prove accurate. For example, statements regarding expected revenue growth and trading margins, market trends and our product pipeline are forward-looking statements. Phrases such as "aim", "plan", "intend", "anticipate", "well-placed", "believe", "estimate", "expect", "target", "consider" and similar expressions are generally intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause actual results to differ materially from what is expressed or implied by the statements. For Smith+Nephew, these factors include: risks related to the impact of COVID-19, such as the depth and longevity of its impact, government actions and other restrictive measures taken in response, material delays and cancellations of elective procedures, reduced procedure capacity at medical facilities, restricted access for sales representatives to medical facilities, or our ability to execute business continuity plans as a result of COVID-19; economic and financial conditions in the markets we serve, especially those affecting health care providers, payers and customers (including, without limitation, as a result of COVID-19); price levels for established and innovative medical devices; developments in medical technology; regulatory approvals, reimbursement decisions or other government actions; product defects or recalls or other problems with quality management systems or failure to comply with related regulations; litigation relating to patent or other claims; legal compliance risks and related investigative, remedial or enforcement actions; disruption to our supply chain or operations or those of our suppliers (including, without limitation, as a result of COVID-19); competition for qualified personnel; strategic actions, including acquisitions and dispositions, our success in performing due diligence, valuing and integrating acquired businesses; disruption that may result from transactions or other changes we make in our business plans or organisation to adapt to market developments; and numerous other matters that affect us or our markets, including those of a political, economic, business, competitive or reputational nature. Please refer to the documents that Smith+Nephew has filed with the U.S. Securities and Exchange Commission under the U.S. Securities Exchange Act of 1934, as amended, including Smith+Nephew's most recent annual report on Form 20-F, for a discussion of certain of these factors. Any forward-looking statement is based on information available to Smith+Nephew as of the date of the statement. All written or oral forward-looking statements attributable to Smith+Nephew are qualified by this caution. Smith+Nephew does not undertake any obligation to update or revise any forward-looking statement to reflect any change in circumstances or in Smith+Nephew's expectations.

◊ Trademark of Smith+Nephew. Certain marks registered US Patent and Trademark Office.

References

References

  1. Smith+Nephew 2021.Validation, FAST-FIX FLEX. Internal Report. 15010267 Rev A.
  2. Smith+Nephew 2021.Validation, FAST-FIX FLEX. Attachment B. Internal Report. 15010267 Rev A.
  3. Smith+Nephew 2021.FAST-FIX FLEX- Surgeon Surveys. Internal Memo.
  4. Pengas IP, Assiotis A, Nash W. et al. Total Meniscectomy in Adolescents: A 40 Year Follow-up. JBJS 2012;94-B:1649-54
  5. https://journals.sagepub.com/doi/abs/10.1177/0363546520935453
  6. Lee, WQ, Gan JZW, Lie, TTD. Save the meniscus- Clinical outcomes of meniscectomy versus meniscal repair. Journal of Orthopaedic Surgery. 2019;27(2):1-6.
  7. Smith+Nephew 2021.Report, Peak Temperature Comparative Study, FASTSEAL 6.0 and Aquamantys 6.0. Internal Report. 110180-02 Rev A.
  8. Marulanda GA, Ulrich SD, Seyler TM, Delanois RE, Mont MA. Reductions in blood loss with a bipolar sealer in total hip arthroplasty. Expert Rev Med Devices. 2008;5(2):125-131.
  9. Derman PB, Kamath AF, Lee GC. Saline-coupled bipolar sealing in revision total knee arthroplasty for infection. Am J Orthop (Belle Mead NJ). 2013;42(9):407-411.
  10. Smith+Nephew. The ABLE◊ (advanced anterior approach): a retrospective case series. Clinical and Medical Affairs Evidence Outcomes Report. Published internal document. 2021. EO.REC.PCSgen.001.v1
  11. Bokor DJ, Sonnabend D, Deady L, et al. Evidence of healing of partial-thickness rotator cuff tears following arthroscopic augmentation with a collagen implant: a 2-year MRI follow-up. Muscles, Ligaments Tendons J. 2016;6(1):16-25.
  12. Schlegel TF, Abrams JS, Bushnell BD, Brock JL, Ho CP. Radiologic and clinical evaluation of a bioabsorbable collagen implant to treat partial-thickness tears: a prospective multicenter study. J Shoulder Elbow Surg. 2018 27(2):242-251.
  13. Van Kampen C, Arnoczky S, Parks P, et al. Tissue-engineered augmentation of a rotator cuff tendon using a reconstituted collagen scaffold: a histological evaluation in sheep. Muscles Ligaments Tendons J. 2013;3(3):229-235.
  14. Bokor DJ, Sonnabend DH, Deady L, et al. Healing of partial-thickness rotator cuff tears following arthroscopic augmentation with a highly porous collagen implant: a 5-year clinical and MRI follow-up. Muscles, Ligaments Tendons J. 2019;9(3):338-347.
  15. McElvany MD, McGoldrick E, Gee AO, Neradilek MB, Matsen FA, 3rd. Rotator cuff repair: published evidence on factors associated with repair integrity and clinical outcome. Am J Sports Med. 2015;43(2):491-500.
  16. Thon SG, O’Malley L, O’Brien MJ, Savoie FH. Evaluation of Healing Rates and Safety With a Bioinductive Collagen Patch for Large and Massive Rotator Cuff Tears: 2-Year Safety and Clinical Outcomes. Am J Sports Med 2019;47(8):1901-1908.
  17. Arnoczky SP, Bishai SK, Schofield B, et al. Histologic Evaluation of Biopsy Specimens Obtained After Rotator Cuff Repair Augmented With a Highly Porous Collagen Implant. Arthroscopy. 2017;33(2):278-283
  18. Smith+Nephew 2021.CAP-FIX Suture Passer Claims Testing Part 2 (Design Validation). Internal Report. 15011184 Rev A.
  19. Smith+Nephew 2021.CAP-FIX Suture Passer Claims Testing Part 1 (Design Verification). Internal Report. 15011185 Rev A.

Title

Text

Explore